ViroPharma dosing patients in phase 2 trial combination of HCV-796, pegylated interferon

By Jennifer Lanning Drey

Portland, Ore., Nov. 10 - ViroPharma, Inc. is dosing patients in a phase 2 clinical trial of HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV) polymerase inhibitor, Colin Broom, ViroPharma's chief scientific officer, said Friday at the ThinkEquity Partners Think Tank Conference in New York.

During the conference, Broom outlined HCV-796's progression through early clinical trails, which have demonstrated that the drug has antiviral activity in treatment-naïve adults across multiple genotypes with a peak response in patients dosed at the 500 mg to 1,000 mg BID dose range.

Further studies have shown that pegylated interferon has additive activity with HCV-796 across multiple genotypes, Broom said.

The current phase 2 clinical trial is focused on genotype 1 treatment naïve patients and will assess the safety, tolerability, pharmacokinetic profile and antiviral activity of HCV-796 in combination with pegylated interferon, alfa-2b plus ribavirin compared to the current standard of care, he said.

The trial will have three arms, one of which will be non-responders.

ViroPharma will obtain data at weeks four, 12, 24 and 48 and may add additional cohorts, depending on the data at 12 weeks, he said.

ViroPharma is a biopharmaceutical company based in Exton, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.